NCT07169396Recruiting
Identifying Genetic Targets in Gynecological Tumors
Identification of Genetic Targets in Gynecological Tumors Via a Triple in Silico Ex-vivo / in Vivo Approach
Source: ClinicalTrials.gov · Last updated 24 Jul 2026
Brief summary (registry, in English)
This observational study aims to identfy genetic targets involved in the pathogenesis of gynecological tumors, with a focus on high-grade serous ovarian carcinoma. Using a triple approach - in silico, ex vivo and in vitro - the study will investigate the role of gonadotropins and their related signaling pathways in the epithelial ovarian cancers. Gene and protein expression levels will be evaluated through transcriptomic analysis, immunohistochemistry and functional assays on tumor cell lines. The goal is to uncover potential diagnostic or therapeutic targets in gynecological malignancies.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 180 (estimated)
- First submitted
- 29 Aug 2025
- Start date
- 17 Nov 2021
- Primary completion date
- 17 Nov 2021
- Lead sponsor
- Azienda USL Reggio Emilia - IRCCS
- Diseases
- Ovarian cancer
- NCT number
- NCT07169396
What you commit to
- Study type: Observational
- Planned participants: 180
- From 17 Nov 2021 to the primary completion date, 17 Nov 2021
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Refusal to sign informed consent
- Diagnosis of low-grade or non-epithelial ovarian tumors
- Patients whose clinical or pathological data are unavailable or insufficient for study inclusion
Who the study is looking for
- Adult women ≥18 years old
- Histologically confirmed diagnosis of epithelial ovarian cancer (including high- grade serous, endometrioid, mucinous, clear cell, or mesonephric-like histotypes)
- Signed informed consent (for prospective cases) or ethically approved waiver (for retrospective samples)
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Azienda USL IRCCS di Reggio Emilia Coordinator of this site? Confirm its status | Reggio Emilia | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.